PubRank

Raphael Mechoulam

Author PubWeight™ 93.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009 2.32
2 Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006 1.95
3 Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007 1.70
4 A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004 1.67
5 Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 2004 1.59
6 Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010 1.56
7 N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 2006 1.52
8 Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 2003 1.50
9 A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 2004 1.43
10 Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 2007 1.30
11 Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006 1.28
12 Cannabinoids in health and disease. Dialogues Clin Neurosci 2007 1.28
13 CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 2005 1.25
14 Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 2011 1.24
15 Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002 1.20
16 Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005 1.19
17 The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2005 1.19
18 The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008 1.18
19 Endocannabinoids and traumatic brain injury. Br J Pharmacol 2011 1.14
20 Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009 1.11
21 Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 2003 1.11
22 Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2007 1.09
23 Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013 1.08
24 The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) 2007 1.08
25 Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 2010 1.08
26 Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 2003 1.07
27 Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2006 1.06
28 Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 2003 1.06
29 Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2011 1.05
30 Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 2002 1.05
31 A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol 2012 1.04
32 The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2007 1.04
33 Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol 2009 1.01
34 Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006 1.01
35 Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 2004 1.01
36 Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 2005 1.00
37 Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011 1.00
38 Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 2008 0.99
39 Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 2007 0.99
40 Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A 2010 0.99
41 Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009 0.99
42 Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav 2005 0.97
43 Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 2007 0.97
44 Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab 2008 0.96
45 Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2005 0.96
46 N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab 2011 0.95
47 Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007 0.95
48 Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002 0.94
49 CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 2011 0.94
50 Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 2003 0.94
51 N-Acyl amino acids and their impact on biological processes. Biofactors 2014 0.93
52 Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol 2007 0.93
53 Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011 0.93
54 A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 2006 0.92
55 Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002 0.92
56 Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev 2007 0.92
57 Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J 2007 0.91
58 Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology 2005 0.91
59 Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol 2008 0.91
60 HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther 2007 0.90
61 Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol 2012 0.89
62 Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) 2011 0.88
63 Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol 2011 0.88
64 Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol 2008 0.87
65 Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem 2010 0.87
66 Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 2004 0.87
67 Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci 2003 0.87
68 Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 2008 0.86
69 Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 2008 0.84
70 N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab 2013 0.83
71 Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berl) 2007 0.83
72 Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology 2005 0.83
73 The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis 2007 0.82
74 Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006 0.82
75 Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 2003 0.81
76 Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Res Bull 2005 0.81
77 The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci 2008 0.81
78 A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. J Pharmacol Exp Ther 2007 0.81
79 Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem 2005 0.80
80 (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol 2004 0.80
81 Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 2014 0.79
82 The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 2003 0.79
83 Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci 2011 0.78
84 PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I. Inflammopharmacology 2004 0.77
85 Cannabis--a valuable drug that deserves better treatment. Mayo Clin Proc 2012 0.77
86 Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression. World J Biol Psychiatry 2013 0.77
87 Intraperirhinal cortex administration of the synthetic cannabinoid, HU210, disrupts object recognition memory in rats. Neuroreport 2015 0.76
88 Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells. J Basic Clin Physiol Pharmacol 2016 0.76
89 Are the endocannabinoid-like compounds N-acyl aminoacids neuroprotective after traumatic brain injury? J Basic Clin Physiol Pharmacol 2016 0.76
90 Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury. J Neuroimmune Pharmacol 2015 0.76
91 Prohedonic Effect of Cannabidiol in a Rat Model of Depression. Neuropsychobiology 2016 0.75
92 Multiple sclerosis may disrupt endocannabinoid brain protection mechanism. Proc Natl Acad Sci U S A 2006 0.75
93 CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol. Ann N Y Acad Sci 2015 0.75
94 Correction: Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. PLoS One 2016 0.75
95 [Endocannabinoids and psychiatric disorders: the road ahead]. Rev Bras Psiquiatr 2010 0.75
96 Conversation with Raphael Mechoulam. Addiction 2007 0.75
97 The promise of advances in the field of endocannabinoids. Neuro Endocrinol Lett 2004 0.75
98 Cannabis - the Israeli perspective. J Basic Clin Physiol Pharmacol 2016 0.75
99 Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect? Neurochem Res 2005 0.75
100 The Endocannabinoid System: A Look Back and Ahead. Handb Exp Pharmacol 2015 0.75